English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/220537
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Tenofovir and remdesivir ensemble docking with the SARS-CoV-2 polymerase and template-nascent RNA

AuthorsPablo M de Salazar; Javier Ramos; Victor L. Cruz; Rosa Polo; Julia del Amo; Javier Martinez-Salazar
RNA polymerase
Issue Date28-Sep-2020
AbstractRepositioning of remdesivir and tenofovir against COVID-19 has shown only partial evidence of improving clinical outcomes, in clinical trials and observational studies respectively. The rationale behind this inconsistent efficacy remains unknown. Here, we developed an ensemble docking approach for the active triphosphate forms of both antivirals with the SARS-CoV-2 polymerase and the RNA chain complex, under the hypothesis that clinical observation could rely on the specificities of the drug-target interaction. Our model framework allowed accurate reconstruction of the remdesivir ensemble, which presented the strongest binding affinity and pose stability close to the natural counterpart dATP. We further observed a set of features of the tenofovir complex that suggests functional yet suboptimal interaction, likely resulting in limited viral inhibition in the absence of high intracellular concentration at target tissues. Our findings provide rationale for the mixed effectiveness of tenofovir-based compounds against SARS-CoV-2 and underscore the relevance of the intracellular availability of the nucleotide analogues relative to viral tropism.
Appears in Collections:(CFMAC-IEM) Artículos
Files in This Item:
File Description SizeFormat 
483674.pdfPreprint (https://www.authorea.com/doi/full/10.22541/au.160133726.63184055)618,83 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.